SOURCE: Rheologics Technologies, Inc.

April 30, 2007 09:47 ET

Rheologics Announces Book Publication on the Origin of Cardiovascular Disease by Chairman Dr. Kenneth Kensey

A Pivotal Step in Educating Physicians on an Overlooked Risk Factor for Heart Disease and Stroke

EXTON, PA -- (MARKET WIRE) -- April 30, 2007 -- Rheologics Technologies, Inc. ("Rheologics" or the "Company") (PINKSHEETS: RTGI), the leader in the study of blood viscosity and its relationship to cardiovascular disease, announces today the publication of "The Origin of Atherosclerosis: What Really Initiates the Inflammatory Process," a book by Rheologics Chairman Kenneth R. Kensey, MD, and Young I. Cho, PhD. In development for more than a decade, "The Origin of Atherosclerosis" is a far-reaching investigation and review of risk factors for cardiovascular disease, underscoring the importance of whole blood viscosity -- an overlooked, basic biological parameter that the authors believe may be the unifying risk factor and root cause of the disease.

The book includes a detailed description of The Protective Adaptation Theory which presents how thick and viscous blood flow is a primary source of stress and injury to the vessels of the body, causing damage and triggering inflammation on a systemic basis throughout the body. Furthermore, the authors consider that because of their proximity to the heart, the large vessels feeding the heart and brain may be serving as shock absorbers for thick and viscous blood, which may explain the especially pronounced injury to those arteries and be ultimately responsible for heart attacks and strokes.

The book also features chapters on hemodynamics -- the principles of blood flow, the importance of the work of the heart, and a sweeping review of peer-reviewed published literature with respect to the clinical significance of whole blood viscosity as it relates to cardiovascular disease, heart attacks, strokes, limb amputations, as well as the conventional risk factors such as high blood pressure, cholesterol, smoking, diabetes, obesity and age. The authors describe the technologies used to measure whole blood viscosity and historical challenges in blood viscosity measurements, as well as provide a therapeutic vision for increasing the efficiency of the heart.

About the Authors

A cardiologist by training, Kenneth R. Kensey, M.D., is a pioneer and recognized leader in medical product development. He is Chairman and Chief Scientific Officer of Rheologics, Inc. (formerly known as Visco Technologies, Inc.) and was also co-founder of Kensey-Nash Corporation, a listed Pennsylvania-based company. At Kensey-Nash Corp., his track record of breakthrough innovations included the development of products in the medical device field such as: the Kensey Catheter for Dynamic Angioplasty, the AngioSeal™ (the leading femoral artery puncture closure device, marketed by St. Jude Medical). Dr. Kensey's devices are in use worldwide. During his tenure as CEO of Kensey-Nash, Dr. Kensey was instrumental in facilitating joint ventures with Baxter Health Care, Johnson & Johnson, American Home Products, Cordis, and Tyco Medical. Dr. Kensey is the inventor or co-inventor in more than 130 patent filings with more than 50 patents issued. He has moderated and lectured at a variety of radiologic, cardiologic, and surgical medical meetings worldwide and has been a featured guest speaker at major medical institutions throughout the United States, Europe and Asia. His publications include contributions to five medical books and nineteen journal articles such as the Journal of Invasive Cardiology and the Review of Scientific Instruments. He is the author of "The Blood Thinner Cure: A Revolutionary Seven Step Lifestyle Plan for Stopping Heart Disease and Stroke" and "The Origin of Atherosclerosis."

A fluid dynamist by training, Young I. Cho, Ph.D., is Professor of Mechanical Engineering & Mechanics at Drexel University and has served Dr. Kensey's research partner for nearly two decades. Dr. Cho initiated his research in blood viscometry as a member of the technical staff at NASA's Jet Propulsion Laboratory at the California Institute of Technology, where he was part of the space medicine program and responsible for a range of experiments to determine the effect of space travel on the blood viscosity of astronauts. In 1986, Dr. Cho held a joint faculty appointment at the Argonne National Laboratory under the U.S. Department of Energy to develop a degradation-free non-Newtonian fluid. In 1993, he was nominated by the U.S. DoE and elected as the chairman of the Advanced Fluid Committee under the International Energy Agency. Dr. Cho has authored/co-authored approximately 150 papers in the area of heat transfer, fluid mechanics, rheology, aerodynamics, acoustics, combustion and energy and is a reviewer for a number of peer-review journals.

"The Origin of Atherosclerosis: What Really Initiates the Inflammatory Process" is currently available for purchase through Rheologics' corporate offices and will soon be available through bookstores and online distributors. Contact Rheologics at 610-524-5427 or email info@rheologics.com for more information.

About Rheologics Technologies, Inc.

Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventive diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at www.rheologics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.

Contact Information